To study the effect of Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
We did a randomized, double-blind, placebo-controlled trial to assess effect of one intravenous dose of cord blood MNCs compared with placebo in reducing incidence of BPD in very preterm neonates.We enrolled preterm neonates less than 32 weeks of GA at neonatal intensive care units (NICUs) in Guangdong Women and Children Hospital within the first 24 postnatal hours. Patients were randomly assigned by 1:1 to receive either (5×107cells/kg ACBMNC or normal saline intravenously within 24 hours after birth according to a computer-generated schedule. The primary endpoint was efficacy at 36 GA or discharge home and all analyses were done by intention to prevent.MNCs viability was also tested before transfusion
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
62
Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
0.9% Sodiun Chloride in control group
Jie Yang
Guangzhou, Guangdong, China
number of patients without bronchopulmonary dysplasia
bronchopulmonary dysplasia incidence
Time frame: at 36 weeks of postmenstrual age or discharge home, whichever came first
number of patients who died, severe bronchopulmonary dysplasia
mortaliity rate
Time frame: at 36 weeks of postmenstrual age
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.